Ashwagandha vs Shankhpushpi for Anxiety
Ashwagandha has placebo-controlled anxiety trials; shankhpushpi has tradition, not trials. Evidence comparison, dosage, and safety.
Two Ayurvedic heavyweights, two very different evidence stories. Ashwagandha (Withania somnifera) has some of the best anxiety-trial data of any herb — randomized trials measuring validated stress scales and cortisol. Shankhpushpi (Convolvulus pluricaulis, officially; regionally Evolvulus alsinoides or Clitoria ternatea) is a classic medhya rasayana used for mental calm, but its human evidence is mostly open-label. If anxiety is the goal, the comparison isn't close on evidence — but shankhpushpi's traditional role and safety profile make it worth understanding. Here's the honest breakdown.
Head-to-Head Comparison Table
| *Ashwagandha (Withania somnifera)* | *Shankhpushpi (C. pluricaulis etc.)* | |
|---|---|---|
| Traditional role | Adaptogen; stress, anxiety, sleep | Medhya rasayana; mental calm, clarity |
| Anxiety RCT evidence | Multiple RCTs: Chandrasekhar 2012 (PSS −44.0%, cortisol −27.9%), Salve 2019 (250/600 mg, 8 wks), Pratte 2014 systematic review of 5 trials, Langade 2019 (insomnia, 10 wks) | Open-label studies only (ADDF: 2 open-label studies; no RCTs identified) |
| Cortisol data | Measured reductions in RCTs | Not established in human trials |
| Effect onset | Measured at 8–10 weeks in trials (no trial demonstrated a 2–4-week onset) | Not trial-defined |
| Standardized trial dose | 250–600 mg/day root extract (KSM-66 / Sensoril-type) | No consensus trial dose |
| Identity stability | Stable — W. somnifera | Contested — 3+ species used regionally |
| Biggest caveat | Thyroid and liver cautions in case reports; interacts with sedatives (NCCIH) | Thin human-trial evidence; identity uncertainty |
Ashwagandha for Anxiety: The Trial Record
Ashwagandha's anxiety evidence is genuinely trial-backed, which sets it apart:
- Chandrasekhar et al. 2012 — randomized, double-blind, placebo-controlled trial (n=64); 300 mg high-concentration full-spectrum root extract twice daily for 60 days reduced Perceived Stress Scale scores by 44.0% (vs 5.5% placebo, p<0.0001) and serum cortisol by 27.9% (vs 7.9% placebo, p=0.002).
- Salve et al. 2019 — 8-week RCT in 60 stressed adults (baseline PSS >20); 250 mg and 600 mg/day of root extract both reduced PSS scores and cortisol vs placebo (greater effects at 600 mg) and improved sleep quality.
- Pratte et al. 2014 — systematic review of 5 human RCTs of ashwagandha for anxiety/stress: all five reported greater score improvements than placebo, but unclear/high risk of bias and heterogeneous design prevented a meta-analysis, so the evidence should be treated with caution.
- Langade et al. 2019 — double-blind, randomized, placebo-controlled study (n=60; 40 test, 20 placebo) in adults with insomnia and anxiety; 300 mg root extract twice daily for 10 weeks improved sleep-onset latency, sleep efficiency, sleep quality, and Hamilton Anxiety (HAM-A) scores vs placebo at 10 weeks (5-week sleep-onset latency did not separate from placebo).
- Extracts: trials used named standardized extracts — KSM-66 (root-only, ≥5% withanolides) and Sensoril (root+leaf, ≥10% withanolides). No direct head-to-head anxiety trial of KSM-66 vs Sensoril has been published, so superiority claims for either extract are unsupported.
The pattern: effects were measured at 8–10 weeks on validated scales — not just "feels calmer" anecdote. Interim trial timepoints (Salve's 4-week PSS, Langade's 5-week sleep-onset latency) did not separate from placebo, so a 2–4-week onset claim isn't supported by the trial data.
Shankhpushpi for Anxiety: Tradition vs Trials
Shankhpushpi's calming reputation is traditional rather than trial-established. It is one of Ayurveda's classic medhya rasayanas (brain tonics); traditional use centers on mental calm, reducing stress and anxiety, and insomnia (ADDF Cognitive Vitality dossier). The human studies identified in published reviews are open-label, without placebo control — ADDF's search found 2 open-label clinical studies and no randomized controlled trials of shankhpushpi at all.
That's not nothing — open-label studies still report symptom improvement — but it's a fundamentally weaker evidence tier than ashwagandha's placebo-controlled trials with validated scales and biomarker (cortisol) data.
Honest framing: if someone finds shankhpushpi calming, the traditional use case supports that experience; but for evidence-based anxiety management, ashwagandha is the defensible first pick between the two.
⏱ Which Works Faster?
Ashwagandha: trial timepoints show benefits at 8–10 weeks, with no trial demonstrating an earlier onset — interim measures at 4–5 weeks did not separate from placebo. Commit to at least 8 weeks before judging. Shankhpushpi has no trial-defined timeline, so there's no honest comparison to make — don't trust a product that gives shankhpushpi a precise onset week.
Dosage Comparison
| Ashwagandha | Shankhpushpi | |
|---|---|---|
| Trial-derived dose | 250–600 mg/day standardized root extract, split into two doses | None established |
| Traditional dose | Root powder ~3–6 g/day (per the site's ashwagandha guide) | Powder ~3–6 g/day (per the site's shankhpushpi guide) |
| Duration in trials | 8–10 weeks | Not trial-defined |
| Titration | Start low; GI upset (stomach upset, diarrhea) and drowsiness possible (NCCIH) | Start low; generally well tolerated |
Safety Comparison
Ashwagandha — more data, more documented cautions:
- Case reports of liver injury (rare) — NCCIH notes "a number of cases that link liver injury to ashwagandha supplements"; Björnsson et al. 2020 published a case series (PMID 31991029). Thyroid hormone increases reported (Sharma et al. 2018 RCT: TSH −17.4%, T4 +19.6%, T3 +41.5%) — NCCIH does not recommend use in people with thyroid disorders, and it may interact with thyroid hormone medications.
- May potentiate sedatives — NCCIH lists sedatives among documented interactions; trial adverse events included drowsiness.
- Avoid in pregnancy — NCCIH advises against use in pregnancy and while breastfeeding; long-term safety data are lacking.
- Autoimmune conditions: NCCIH does not recommend use — possible immune stimulation.
Shankhpushpi — favorable animal toxicology, thinner human data:
- C. pluricaulis: no mortality in animal toxicology up to 5,000 mg/kg; E. alsinoides: no mortality or organ toxicity up to 2,000 mg/kg in acute and 28-day subacute studies (Siripurapu et al. 2005).
- Thyroid caution from Panda & Kar 2001 — root extract inhibited T3 production in levothyroxine-treated female mice (animal study; not a human safety signal).
- No human case reports of liver/kidney injury identified.
- Excessive intake above ~12 g/day flagged on precautionary grounds by the site's own shankhpushpi guide (excessive sedation, blood-pressure drop, GI upset, possible thyroid interference with medications).
Bottom line on safety: ashwagandha's cautions are better documented because it's better studied; shankhpushpi's profile looks clean but rests on thinner human evidence. Both warrant prescriber input if you take thyroid medication, sedatives, or are pregnant.
How to Choose
- Anxiety/stress as the primary goal → ashwagandha. It has the RCTs, the validated scales, and the cortisol data. This is the evidence-based pick.
- Gentle traditional calming use, mild mental fatigue, and you're comfortable with tradition-grade evidence → shankhpushpi (species-identified product: Convolvulus pluricaulis).
- Sleep-focused anxiety → ashwagandha (Langade 2019 insomnia/anxiety trial).
- Combining: no placebo-controlled trials have tested ashwagandha + shankhpushpi together; the combination appears in traditional polyherbal formulas and commercial products but is unstudied as an anxiety pairing. Both can cause drowsiness — introduce separately and don't drive drowsy.
❓ Frequently Asked Questions
📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.
📚 Clinical Research & Sources
- Chandrasekhar K et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." *Indian J Psychol Med*. 2012;34(3) — PSS −44.0%, cortisol −27.9%[Source ↗]
- Salve J et al. "Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study." *Cureus*. 2019;11(12):e6466 — PMID 32021735[Source ↗]
- Pratte MA et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera)." *J Altern Complement Med*. 2014;20(12):901–908 — systematic review of 5 RCTs; no meta-analysis[Source ↗]
- Langade D et al. "Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study." *Cureus*. 2019;11(9):e5797[Source ↗]
- NCCIH. "Ashwagandha: Usefulness and Safety" — safety, pregnancy, liver injury, sedative interactions[Source ↗]
- Alzheimer's Drug Discovery Foundation, Cognitive Vitality. "Shankhpushpi" — 2 open-label studies; no RCTs[Source ↗]
- Ayurvedic Pharmacopoeia of India — Shankhpushpi botanical identity (*Convolvulus pluricaulis*), as cited in a published review[Source ↗]
- Panda S, Kar A. "Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis." *Horm Metab Res*. 2001;33(1):16–18 — as cited in a PMC review[Source ↗]
Explore the Full Remedy Database
Browse 500+ organic alternatives for health, wellness, and natural living.
Browse All Remedies →